More articles about: Rogel Cancer Center

Researchers from the University of Michigan Health Rogel Cancer Center have discovered a biomarker that could help identify which renal cancer patients have a higher risk of recurrence.

Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.

The availability of clinical trials of new treatments for cancer varies greatly by geography, and a new study shows more socially vulnerable areas have far fewer.

Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X

Using a chip to process blood samples, doctors can monitor the amount of cancer cells in a patient’s blood to determine how well a treatment is working by the fourth week, according to a new study.

Research from Michigan Medicine experts is shedding light and potentially expanding options for patients living with an aggressive childhood cancer.

Drs. Elena Stoffel and Jennifer Griggs, co-principal investigators of the Michigan Genetic Hereditary Testing (MiGHT) Study, discuss the importance of knowing your family health history.

Michigan Medicine neurosurgeon, Nicholas Szerlip, discusses cancer metastasis to the spine and how the Rogel Cancer Center is addressing this through their Metastatic Spine Oncology clinic.

In this episode, head and neck surgical oncologist Andrew G. Shuman, M.D., FACS, HEC-C, discuses the current cancer drug shortages and how they’re impacting patient care nationwide.

For thyroid cancer, experts examine the current state of overdiagnosis, new therapies, health equity concerns and more.

University of Michigan School of Public Health professor, Dana Dolinoy, explains the role of epigenetics in environmental exposures and health.

University of Michigan Rogel Cancer Center urological oncologist, Lindsey Herrel, MD, discusses what people should know about bladder cancer.

University of Michigan Health Rogel Cancer Center physician assistant, Maureen Pickle, talks about screening, treatment and understanding one’s risk for colon and rectal cancer.

Lynn Henry, M.D., Ph.D., disease lead of the Rogel Cancer Center’s Breast Cancer Program, discusses metastatic breast cancer. This is the process of breast cancer that has spread to another part of the body, including bones, liver, lung, and brain.

In 2011, Ruth was diagnosed with multiple myeloma. Understanding that it is an incurable disease, she puts her best foot forward by starting each day with gratitude, receiving her treatment, and staying healthy. She cherishes the opportunity it is to wake up each day and choose her inner strength. This is her story and advice to others.